eculizumab in a sentence

• Eculizumab is a humanized monoclonal antibody against the complement protein C5.
• The volume of distribution of eculizumab in humans approximates that of plasma.
• There are also reports of eculizumab being used to treat cold agglutinin disease.
• More recently eculizumab and treprostinil have been employed.
• Eculizumab was developed and is manufactured and marketed by Connecticut-based Alexion Pharmaceuticals.
• Life-threatening and fatal meningococcal infections have occurred in patients who received eculizumab.
• Eculizumab inhibits terminal complement activation and therefore makes patients vulnerable to infection with encapsulated organisms.
• Eculizumab has exclusivity rights until 2017 which protects it from competition from biosimilar applications until 2017.
• Eculizumab was associated with mean increases in platelet count and eGFR from baseline to 26 weeks.
• Alexion also initiated an eculizumab access program whereby the company provided eculizumab free of charge throughout the crisis.
• It's difficult to see eculizumab in a sentence .
• Alexion also initiated an eculizumab access program whereby the company provided eculizumab free of charge throughout the crisis.
• The study was designed to include all patients treated with eculizumab during the 2011 STEC-HUS outbreak.
• In Study 1, eculizumab inhibited complement-mediated TMA activity in all 17 patients through 26 weeks.
• Response to eculizumab is often immediate and dramatic, but has been of limited duration in all so treated.
• Additionally, at a median duration of almost 2 years, all patients receiving chronic eculizumab therapy remain alive.
• Eculizumab treatment is recommended to continue for the patient s lifetime, unless discontinuation of therapy is clinically indicated.
• Based on established thresholds, the opportunity cost of funding eculizumab is 102.3 discounted QALYs per patient funded ."
• The drug eculizumab ( trade name "'Soliris "') prevents cleavage of C5 into C5a and C5b.
• No patient on chronic eculizumab therapy in the extension to Study 2 required PE / PI or progressed to ESRD or dialysis.
• Eculizumab is a recombinant humanized monoclonal IgG2 / 4 antibody that selectively targets and inhibits the terminal portion of the complement cascade.